Contracts › 75A50125C00010
75A50125C00010: Clinical Development of OX390 (ATIPAMEZOLE) As an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, Medetomidine, and Other ?2 Agonists
Awarded to Orexo Us Inc by Office of Assistant Secretary for Preparedness and Response.
$11.5Mobligated
$53.9Mpotential value
31 December 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50125C00010 |
|---|---|
| Awardee | Orexo Us Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NJ |
| Offers received | 1 |
| Period of performance | 24 September 2025 to 31 December 2027 |
| Potential end | 04 February 2032 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record